TD Cowen Raises Royalty Pharma Price Target to $80
The target increase and stated growth rationale are bullish, but the signal rests on a single analyst opinion.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The target increase and stated growth rationale are bullish, but the signal rests on a single analyst opinion.
What happened, with direct paths to the underlying reporting
TD Cowen raised its RPRX target to $80, about 16% above the posted price of $68.76, citing growth and pipeline upside.
Target: $80
Posted price: $68.76
Analyst firm: TD Cowen
Analyst: Steve Scala
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.